v3.26.1
Segment Information - Schedule of Segment Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Revenues $ 0   $ 3,181   $ 0 $ 8,573
Research and development 37,199   32,807   70,734 69,249
Other segment expenses [1] 18,142   9,227   30,122 18,053
Net loss (55,341) $ (45,514) (38,853) $ (39,876) (100,856) (78,729)
Vopimetostat direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development 12,345   5,577   21,677 11,038
TNG456 direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development 2,451   1,646   4,515 2,970
TNG260 direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development [2] 1,343   1,809   3,351 3,539
TNG961 direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development [3] 59   1,572   467 3,793
TNG908 direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development [4] 60   1,235   641 2,947
Discovery direct program expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development 2,414   2,709   4,287 7,388
Personnel-related expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development 13,981   12,834   26,911 26,684
Facilities and other related expenses - R&D [Member]            
Segment Reporting [Line Items]            
Research and development $ 4,546   $ 5,425   $ 8,885 $ 10,890
[1] Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.
[2] In May 2026, the Company announced it would deprioritize future development and resources allocated to the Phase 1/2 TNG260 clinical trial given the limited clinical benefit demonstrated in patients.
[3] In May 2026, the Company announced it did not plan to further advance development of TNG961.
[4] In November 2024, the Company announced it stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 relate to previously enrolled patients and close-out clinical trial costs.